Edward Waldron
Impact in
- Oncology top 10%
- CAR-T cell therapy research
Papers in
- Oncology 12
- CAR-T cell therapy research 9
- Peptidase Inhibition and Analysis 2
-
- Histone Deacetylase Inhibitors Research 3
- RNA Interference and Gene Delivery 2
- Co-authors
- Rakesh Awasthi (9 shared papers)Stephan A. Grupp (5 shared papers)Karen Thudium Mueller (7 shared papers)Xia Han (1 shared paper)Patricia A. Wood (2 shared papers)Noelle V. Frey (1 shared paper)Simon F. Lacey (1 shared paper)Carl H. June (2 shared papers)
- Journals
- Blood (3 papers)Journal of Clinical Oncology (2 papers)Cancer Chemotherapy and Pharmacology (2 papers)Cancer Research (2 papers)Clinical Trials (1 paper)
- Partner nations
- United StatesSwitzerlandFrance
In The Last Decade
Edward Waldron
12 papers receiving 345 citations
Peers
Comparison fields: 5 of 38
- Oncology 291
- Hematology 40
- Immunology 63
- Genetics 73
- Molecular Biology 160
Countries citing papers authored by Edward Waldron
This map shows the geographic impact of Edward Waldron's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Edward Waldron with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Edward Waldron more than expected).
Fields of papers citing papers by Edward Waldron
This network shows the impact of papers produced by Edward Waldron. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Edward Waldron. The network helps show where Edward Waldron may publish in the future.
Co-authors
The 25 scholars most cited alongside Edward Waldron, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2017 | 253 | |
| 2 | 2014 | 36 | |
| 3 | 2014 | 30 | |
| 4 | 2015 | 21 | |
| 5 | 2018 | 5 | |
| 6 | 2015 | 3 | |
| 7 | 2023 | 3 | |
| 8 | 2018 | 3 | |
| 9 | 2017 | 3 | |
| 10 | 2018 | 2 | |
| 11 | 2021 | 2 | |
| 12 | 2017 | 1 | |
| 13 | Clinical pharmacology of tisagenlecleucel (CTL019) in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) | 2018 | 0 |
About Edward Waldron
Edward Waldron is a scholar working on Oncology, Molecular Biology, Immunology, Public Health, Environmental and Occupational Health and Hematology, having authored 13 papers that have together received 362 indexed citations. Recurring topics across this work include CAR-T cell therapy research (9 papers), Histone Deacetylase Inhibitors Research (3 papers), Immunotherapy and Immune Responses (3 papers), Acute Lymphoblastic Leukemia research (3 papers), Biosimilars and Bioanalytical Methods (3 papers), RNA Interference and Gene Delivery (2 papers), Biomedical Ethics and Regulation (2 papers) and Peptidase Inhibition and Analysis (2 papers). The work is most often cited by research in Oncology (291 citations), Hematology (40 citations), Immunology (63 citations), Genetics (73 citations) and Molecular Biology (160 citations). Edward Waldron has collaborated with scholars based in United States, Switzerland and France. Frequent co-authors include Rakesh Awasthi, Stephan A. Grupp, Karen Thudium Mueller, Xia Han, Patricia A. Wood, Noelle V. Frey, Simon F. Lacey, Carl H. June, Bruce L. Levine and J. Joseph Melenhorst. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Cancer Research and Clinical Trials.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.